SCHEMBL23828213

SCHEMBL23828213

Cc1ccc2[nH]c3c(c2c1)CN(C(=O)c1cc2ccccc2[nH]1)CC3

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BAZ2B Q9UIF8 2/20 0.65
▸ CFTR P13569 3/20 0.65
▸ LMNA P02545 2/20 0.61
▸ PABPC1 P11940 1/20 0.61
▸ ATM Q13315 1/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.61
▸ NPC1 O15118 2/20 0.57
▸ MAPT P10636 6/20 0.56
▸ ALDH1A1 P00352 6/20 0.56
▸ GAA P10253 4/20 0.56
▸ CASP1 P29466 3/20 0.56
▸ CASP7 P55210 2/20 0.56
▸ MEN1 O00255 3/20 0.55
▸ KMT2A Q03164 3/20 0.55
▸ USP2 O75604 1/20 0.55
▸ KDM4E B2RXH2 1/20 0.55
▸ HPGD P15428 1/20 0.55
▸ HIF1A Q16665 1/20 0.55
▸ TDP1 Q9NUW8 1/20 0.55
▸ SAE1 Q9UBE0 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31020960 1.00 BAZ2B (0.65) BAZ2BCFTRLMNAPABPC1ATM
SCHEMBL21617987 0.89 CFTR (0.76) BAZ2BCFTRLMNAATMSMN1; SMN2
SCHEMBL31020955 0.85 CFTR (0.79) BAZ2BCFTRLMNAPABPC1ATM
SCHEMBL23828252 0.85 CFTR (0.79) BAZ2BCFTRLMNAPABPC1ATM
SCHEMBL31020940 0.84 CFTR (0.61) BAZ2BCFTRLMNAPABPC1ATM
SCHEMBL23828211 0.84 CFTR (0.61) BAZ2BCFTRLMNAPABPC1ATM
SCHEMBL31117415 0.84 BAZ2B (0.72) BAZ2BCFTRLMNAPABPC1ATM
SCHEMBL17938707 0.81 KMT2A (0.67) BAZ2BCFTRLMNAMAPTGAA
SCHEMBL12868355 0.80 BAZ2B (1.00) BAZ2BCFTRLMNAPABPC1ATM
SCHEMBL3424575 0.80 BAZ2B (0.81) BAZ2BCFTRLMNAPABPC1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3820867-B1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS FONDAZIONE ST ITALIANO TECNOLOGIA (IT) 2023-09-13 — — EP claimed
US-20210292324-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS ISTITUTO GIANNINA GASLINI (IT) 2021-09-23 — — US claimed
US-11999734-B2 Compounds and compositions for the treatment of cystic fibrosis FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2024-06-04 — — US disclosed
EP-3820867-B1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS FONDAZIONE ST ITALIANO TECNOLOGIA (IT) 2023-09-13 — — EP disclosed
US-20210292324-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS ISTITUTO GIANNINA GASLINI (IT) 2021-09-23 — — US disclosed
US-20210292324-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS ISTITUTO GIANNINA GASLINI (IT) 2021-09-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11999734-B2 Compounds and compositions for the treatment of cystic fibrosis CFTR, ABCB11, ABCC5 BAZ2B 4498/4885CFTR 1/4885LMNA 2957/4885
US-20210292324-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, ABCB11, ABCC5 BAZ2B 4498/4885CFTR 1/4885LMNA 2957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback